Infliximab in the Treatment of Patients With Severe COVID-19 Disease
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
In this trial, patients that are severely affected by the disease COVID-19 will either
receive infliximab, an anti-inflammatory drug, or standard therapy. Infliximab is a drug that
inhibits inflammation by blocking a molecule called TNFα. The patients receive the drug via
an infusion into a vein. The primary goal of this trial is to see whether the drug infliximab
affects how many people died from COVID-19 after 28 days by comparing patients receiving the
drug in addition to standard therapy with patients only receiving standard therapy.
Furthermore, this trial will look at whether the drug is safe to use in these patients,
whether it has an effect on the inflammation and whether it can affect how ill patients are
after surviving the disease.
The trial is conducted in more than one hospital. As COVID-19 is responsible for a global
pandemic, positive results of this trial could affect patients, healthcare and economic
systems worldwide.
Phase:
Phase 2
Details
Lead Sponsor:
Jena University Hospital
Collaborators:
Celltrion German Federal Ministry of Education and Research